Onconetix, Inc. Form 8-K Summary
Business context and reporting period
On May 8, 2024, Onconetix, Inc. received a deficiency notice from Nasdaq regarding continued listing compliance. The notice was based on the Company’s stockholders’ equity reported for the fiscal year ended December 31, 2023. The Form 8-K was signed and filed on May 13, 2024.
Financial metrics and liquidity
- Stockholders’ equity at December 31, 2023: $1,404,476.
- Nasdaq’s minimum stockholders’ equity requirement: $2,500,000.
- The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures.
- The Company also did not meet either alternative compliance standard: at least $35 million in market value of listed securities or at least $500,000 in net income from continuing operations for the relevant periods.
Material changes versus the prior comparable period
The filing does not present a period-over-period income statement or cash flow comparison. The material development is Nasdaq’s determination that the Company was below the continued-listing equity requirement based on its December 31, 2023 financial statements.
Outlook, risks, contingencies, and unusual items
- The deficiency notice had no immediate effect on the Company’s Nasdaq listing.
- The Company had until June 24, 2024 to submit a specific plan to regain and sustain compliance.
- If Nasdaq accepted the plan, it could grant an exception of up to 180 calendar days from the notice date, through approximately November 4, 2024.
- There is no assurance that Nasdaq would accept the plan or that the Company would regain compliance within any extension period.
- If Nasdaq rejected the plan, the Company could appeal to a Nasdaq Hearing Panel.
- Failure to regain compliance, including within any approved extension, could result in delisting of the Company’s securities from Nasdaq.
Key facts investors should verify
- Whether the Company submitted a compliance plan by June 24, 2024.
- Whether Nasdaq accepted the plan or granted an extension through November 4, 2024.
- Subsequent changes in stockholders’ equity, financing activities, and capital structure.
- Any later Nasdaq decision, hearing, compliance determination, or delisting action.
- The filing text does not provide a clear current cash balance, debt balance, or liquidity runway.